BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35124468)

  • 21. Gamma-glutamyl transpeptidase to platelet ratio index is a good noninvasive biomarker for predicting liver fibrosis in Chinese chronic hepatitis B patients.
    Wang RQ; Zhang QS; Zhao SX; Niu XM; Du JH; Du HJ; Nan YM
    J Int Med Res; 2016 Dec; 44(6):1302-1313. PubMed ID: 28322102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aspartate transaminase to platelet ratio index and gamma-glutamyl transpeptidase-to-platelet ratio outweigh fibrosis index based on four factors and red cell distribution width-platelet ratio in diagnosing liver fibrosis and inflammation in chronic hepatitis B.
    Wu X; Cai B; Su Z; Li Y; Xu J; Deng R; Wang L
    J Clin Lab Anal; 2018 May; 32(4):e22341. PubMed ID: 29251384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy.
    Kim MN; Lee JH; Chon YE; Ha Y; Hwang SG
    Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):433-439. PubMed ID: 31490417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Easy Liver Fibrosis Test (eLIFT) for predicting advanced liver fibrosis in patients with chronic hepatitis B.
    Wang J; Chen Z; Yan X; Yang Y; Liu Y; Chen Y; Jia B; Xia J; Xiong Y; Zhang Z; Ding W; Huang R; Wu C
    Discov Med; 2019 Sep; 28(153):149-158. PubMed ID: 31926586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum N-glycan markers for diagnosing liver fibrosis induced by hepatitis B virus.
    Cao X; Shang QH; Chi XL; Zhang W; Xiao HM; Sun MM; Chen G; An Y; Lv CL; Wang L; Nan YM; Chen CY; Tan ZN; Liu XE; Zhuang H
    World J Gastroenterol; 2020 Mar; 26(10):1067-1079. PubMed ID: 32205997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel noninvasive algorithm for the assessment of liver fibrosis in patients with chronic hepatitis B virus infection.
    Zhu MY; Zou X; Li Q; Yu DM; Yang ZT; Huang D; Chen J; Gong QM; Zhang DH; Zhang Y; Chen L; Chen PZ; Zhang XX
    J Viral Hepat; 2017 Jul; 24(7):589-598. PubMed ID: 28130852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic value of FIB-4, aspartate aminotransferase-to-platelet ratio index and liver stiffness measurement in hepatitis B virus-infected patients with persistently normal alanine aminotransferase.
    Tan YW; Zhou XB; Ye Y; He C; Ge GH
    World J Gastroenterol; 2017 Aug; 23(31):5746-5754. PubMed ID: 28883700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.
    Kim WR; Berg T; Asselah T; Flisiak R; Fung S; Gordon SC; Janssen HL; Lampertico P; Lau D; Bornstein JD; Schall RE; Dinh P; Yee LJ; Martins EB; Lim SG; Loomba R; Petersen J; Buti M; Marcellin P
    J Hepatol; 2016 Apr; 64(4):773-80. PubMed ID: 26626497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are non-invasive fibrosis markers for chronic hepatitis B reliable in sub-Saharan Africa?
    Desalegn H; Aberra H; Berhe N; Gundersen SG; Johannessen A
    Liver Int; 2017 Oct; 37(10):1461-1467. PubMed ID: 28222249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GPR, King's Score and S-Index are superior to other non-invasive fibrosis markers in predicting the liver fibrosis in chronic Hepatitis B patients.
    Ekin N; Ucmak F; Ebik B; Tugba Tuncel E; Kacmaz H; Arpa M; Engin Atay A
    Acta Gastroenterol Belg; 2022; 85(1):62-68. PubMed ID: 35304995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Globulin-platelet model predicts significant fibrosis and cirrhosis in CHB patients with high HBV DNA and mildly elevated alanine transaminase levels.
    Li Q; Lu C; Li W; Huang Y; Chen L
    Clin Exp Med; 2018 Feb; 18(1):71-78. PubMed ID: 28884309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic accuracy of different noninvasive scores for detecting advanced fibrosis in chronic hepatitis B.
    Hamidi AA; Oncul A; Ozguven BY; Sevgi DY; Gunduz A; Uzun N; Dokmetas I
    Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1439-1443. PubMed ID: 31033847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel non-invasive score for the prediction of advanced fibrosis in patients with chronic hepatitis B.
    Okdemir S; Cakmak E
    Ann Hepatol; 2022; 27(1):100544. PubMed ID: 34571267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection.
    Li Q; Lu C; Li W; Huang Y; Chen L
    Sci Rep; 2017 Jul; 7(1):5429. PubMed ID: 28710435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brief Report: HIV/HBV Coinfection is a Significant Risk Factor for Liver Fibrosis in Tanzanian HIV-Infected Adults.
    Hawkins C; Christian B; Fabian E; Macha I; Gawile C; Mpangala S; Ulenga N; Thio CL; Ammerman LR; Mugusi F; Fawzi W; Green R; Murphy R
    J Acquir Immune Defic Syndr; 2017 Nov; 76(3):298-302. PubMed ID: 29016448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
    Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
    Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia.
    Paik N; Sinn DH; Lee JH; Oh IS; Kim JH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Liver Int; 2018 Jan; 38(1):68-75. PubMed ID: 28581248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia.
    Vinikoor MJ; Sinkala E; Mweemba A; Zanolini A; Mulenga L; Sikazwe I; Fried MW; Eron JJ; Wandeler G; Chi BH
    Liver Int; 2015 Jul; 35(7):1886-92. PubMed ID: 25581487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of Serum Biomarker Indices for Staging of Hepatic Fibrosis Before and After Venesection in Patients With Hemochromatosis Caused by Variants in HFE.
    Chin J; Powell LW; Ramm LE; Hartel GF; Olynyk JK; Ramm GA
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1459-1468.e5. PubMed ID: 32745684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors.
    Carrieri P; Carrat F; Di Beo V; Bourlière M; Barré T; De Ledinghen V; Pageaux GP; Bureau M; Cagnot C; Dorival C; Delarocque-Astagneau E; Marcellin F; Pol S; Fontaine H; Protopopescu C;
    JHEP Rep; 2022 Jun; 4(6):100481. PubMed ID: 35514789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.